• Cosmeceutical industry forecasts anticipate $73 billion market for cosmetic skin care products utilizing active chemical ingredients by 2023
• Therma Bright is using trademarked infrared head technologies to target skin viruses and establish a protective barrier for the human body’s largest organ
• Company is also exploring cannabidiol’s properties as augmenting agent for thermal technologies in fighting pain

Far from being mere tissue, skin is the human body’s largest and fastest-growing organ and a vital protection against harm to all of the body’s other organs and the systems that regulate their function (http://ibn.fm/4AO39), which provides an obvious reason for trying to keep skin healthy. Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) is focusing its business mission on the development of innovative technologies that strengthen and sustain the body’s outer layer and help people to live healthier lives as a result.

The key to Therma Bright’s vision of enhancing health and wellness is to employ trademarked infrared heat technology against agents that attack the skin, such as insect stings, bites and viruses. The company’s TherOZap technology is a first-generation medical device approved by the U.S. Food and Drug Administration (“FDA”) for the relief of the symptoms of skin pain, itch and inflammation, but Therma Bright has been working on a corollary product that may establish a barrier against stinging and biting insects to combat the Zika virus and other mosquito-borne diseases such as dengue.

Therma Bright is testing final prototypes of the technology against the Zika virus at a research laboratory in a process that’s expected to take several months (http://ibn.fm/KlXYA). Initial pre-clinical test results announced last year, when the company was named Jenex, indicated that Toronto, Canada’s Techna Institute had found TherOZap effective for the inactivation of live Zika virus in culture media and the inhibition of Zika virus infection into cultured cells in vitro, according to a company news release (http://ibn.fm/gSwaT).

Those findings led Robert A. Poggie, a regulatory consultant for the FDA, to declare, “Pre-clinical testing of the TherOZap technology indicates effectiveness in inhibiting Zika virus, which holds promise for the US FDA accepting marketing claims and associated data via 510(k) review,” according to the news release.

A second trademarked Therma Bright technology, InterceptCS, has also received some regulatory recognition for the treatment of cold sores by killing cells infected with the herpes simplex Type 1 virus. Based on a double-blind placebo study, InterceptCS is approved for the claim, “For prevention of cold sores when used within three hours of the onset of the prodrome” by Health Canada. The InterceptCS technology is not, however, approved by the United States’ FDA for any claim of clinical indication, clinical efficacy and/or cure or prevention of disease at this time.

InterceptCS delivers controlled topical heat with no risk of burning the skin as it targets the cold sore virus-infected cells. The company’s technologies are representative of a broader cosmeceutical industry that produces products with cosmetic applications of active potential chemical ingredients.

Industry forecasts anticipate a growing worldwide market for cosmeceuticals, with one prediction forecasting growth at a CAGR of 8.21 percent between 2017 and 2023, when the market is expected to reach about $73 billion (http://ibn.fm/q6Ew2).

Therma Bright is also turning to the positive word of mouth surrounding cannabidiol (“CBD”) for testing the cannabis plant-derived active ingredient in concert with the company’s thermal products as a means of enhancing pain relief therapies (http://ibn.fm/5mAes).

For more information, visit the company’s website at www.ThermaBright.com

• Immersed in competitive U.S. market, PLUS rose from 12th to number one
• PLUS benefits from the expertise of Michelin-star chefs, Ivy League chemists and others
• Company donates a portion of proceeds from limited edition products to the National Park Foundation and the Trevor Project

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) recognized early that the strongest brands in the cannabis industry would emerge from California. California is the largest market in the world, expected to reach $5 billion in legal sales this year. The state also has a long history of medical legalization, making it the most competitive market available. The pressure and challenge of being immersed with the best in the business launched PLUS to the number one best-selling edible brand in California during Q3 2018 (http://ibn.fm/AFfte).

“Plus Products is a cannabis manufacturing product company, and our vision is to build the strongest cannabis brand,” Jake Heimark, CEO and co-founder of PLUS, stated in a Business Television segment (http://ibn.fm/nwIbp). “In the last year, PLUS moved from about 12th in edibles in California to being the number one edible company in what is the largest cannabis market in the world.”

PLUS’ products are exclusively available in California. The company’s cannabis-infused gummy candy is created to support a healthy, active lifestyle and sells in over 200 licensed dispensaries and delivery services.

The company utilizes the expertise of Michelin-star chefs, Ivy League chemists, food manufacturing experts, engineers, machinists, visionaries, creatives, strategists and others in executing its strategy. The goal is to create dosable and delicious products that provide a consistent experience.

PLUS rolls out limited-edition cannabis-infused gummies with the seasons. The current limited edition is Pink Lemonade Refresh, and a portion of the proceeds from this product will be donated to the National Parks Foundation. Last summer, the limited edition was a rainbow sorbet, with a portion of each purchase donated to the Trevor Project, a confidential suicide hotline for LGBT youth.

PLUS focuses on four consistent cannabis-infused gummies sold year-round and exclusively in California:

• Blackberry & Lemon RESTORE
• Sour Watermelon UPLIFT
• Pineapple & Coconut CBD RELIEF
• Sour Blueberry CREATE

Every PLUS product is made from scratch with carefully sourced high-quality extracts and kosher ingredients.

In addition to the company’s rise in the ranks, it was added to the OTCQB Venture Market under the symbol ‘PLPRF’ on January 23, 2019. The company will continue to trade on the Canadian Securities Exchange under the symbol ‘PLUS’.

“We are pleased to be approved to trade on the OTCQB platform and expect to access a greater range of U.S. institutional and retail investors, while at the same time providing U.S. investors access to our securities on a recognized U.S. securities trading platform,” Heimark said in a recent press release (http://ibn.fm/cJeik). “We have a strong U.S. investor base, and this will allow us to provide greater transparency to our current and future shareholders.”

For more information, visit the company’s website at www.PlusProducts.com

• Company recently announced submission of its application for common share listing on the Nasdaq Capital Market
• Uplisting will give the company broader access to international investors, Flowr executives believe
• Further steps are being undertaken to turn Flowr into a truly global company that benefits from serious competitive advantage over other cannabis producers

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Canadian licensed producer of premium cannabis products, announced in February that it has submitted an application for its common shares to be listed on the Nasdaq Capital Market. The company has also filed a Form 40-F registration statement with the U.S. Securities and Exchange Commission (“SEC”), according to a news release (http://ibn.fm/KIXOc).

Various regulatory requirements need to be met for the Nasdaq listing to be finalized. The Canadian Flowr Corporation will need to go through the registration of its common shares with the SEC and an assessment by Nasdaq to determine if Flowr has satisfied its listing requirements.

Until the approval becomes effective, Flowr Corporation shares will continue to trade on the OTC under ticker symbol ‘FLWPF’. Once all regulatory requirements have been fulfilled, a trading date will be made public.

A Nasdaq listing is an important step toward broadening Flowr’s access to international investors, company co-CEO Vinay Tolia said in a news release. So far, the company has made massive progress executing its business plan since going public in 2018. Further steps are being undertaken to turn Flowr into a truly global company, Tolia underlined.

To date, the Canadian cannabis licensed producer has designed and built 17 cultivation facilities. All of them feature innovative technologies and solutions that ensure high yields and low production cost. These facts give Flowr a competitive advantage in a niche that’s quickly expanding.

In the next few years, the cannabis product market is anticipated to go through a number of important changes. A supply glut is anticipated in the Canadian cannabis sector, with supply set to potentially exceed demand by 2020, according to analyst projections (http://ibn.fm/dGxBe). As a result, producers who ensure high yields and cost efficiency will benefit from serious competitive advantage.

Flowr is already registering exceptional yield per square foot in its facilities. Due to its experience and focus on innovative cultivation practices, the company has reached a price point that other cannabis companies may be incapable of achieving.

The company is currently working on optimizing its yield even further. In 2019, Flowr expects to reach a production cost landmark of C$2.05 per gram.

In January 2019, Flowr announced a multilayer supply deal with Shoppers Drug Mart online store. Shoppers Drug Mart is Canada’s largest retail pharmacy chain. There are over 1,300 Shoppers Drug Mart locations across the country, and the partnership will give Shopper’s extensive patient network access to Flowr’s premium medicinal cannabis.

For more information, visit the company’s website at www.Flowr.ca

• Legislative changes have increased the popularity of cannabis products in the U.S. and Canada; as a result, consumers have started looking for high quality and premium-grade developments in the field
• Green Hygienics Holdings is investing in innovative cultivation practices that ensure both the quality and the yield of cannabis
• The company focuses on premium cannabis-derived products obtained via proprietary aeroponics cultivation technology that comes with record low production costs

As the legal cannabis sector expands, competition between companies in the field is also intensifying, with producers and distributors constantly looking for some competitive advantage in order to secure a solid market position. New technologies, especially in regard to cultivation processes, can provide this much sought-after advantage.

One company capitalizing on a proprietary cultivation technique is Green Hygienics Holdings Inc. (OTCQB: GRYN). The company is investing in innovative cultivation technologies that maximize yield and reduce the cost of production – two advantages that give Green Hygienics a unique position on a market that’s defined by a growing demand for premium-grade cannabis products.

Green Hygienics Holdings is quickly establishing itself as a leader in the advancement of science-driven cultivation systems. The company employs a unique aeroponics-based cultivation method through which nutrients are delivered to the exposed roots of the plant. Apart from increasing crop yields, this cultivation method is highly environmentally-friendly. According to Green Hygienics Holdings, aeroponics cultivation uses anywhere between 90 and 95 percent less water than standard agricultural practices. Pesticides and fungicides are also not required.

On top of being more sustainable, this cultivation technique reduces the cost of cannabis production, produces higher yields, ensures better quality and provides more control over the entire process.

As the cannabis market is still relatively young but constantly growing, competition is also intensifying considerably. According to experts, production efficiency and low costs are going to be the primary factors determining the success of cannabis producers in this high-competition environment.

Both of these goals can be accomplished through the adoption of innovative solutions like those used in the Green Hygienics Holdings cultivation methodology. The cost per unit for Green Hygienics Holdings’ production is less than $1. The industry standard for traditional cultivation is anywhere between $2 and $4 per unit.

On top of relying on innovative cultivation, Green Hygienics also invests in the technology that provides a greater degree of control over many aspects of the process.

Quality-controlled commercial cultivation equipment and software provide Green Hygienics with data that can be used to monitor and control the growth of cannabis. Cultivation problems are easy to identify this way, which results in the introduction of immediate measures to rectify the issue.

Green Hygienics expects these innovations to enable to meet its growth goals in 2019. The company intends to continue generating revenue from the cultivation and sale of premium-grade cannabis-derived products. Previously, Green Hygienics announced its intentions to develop and license additional intellectual property assets, make strategic acquisitions and develop globally-trusted consumer brands.

For more information, visit the company’s website at www.GreenHygienicsHoldings.com

• Sproutly Canada focusing on recreational cannabis beverage, edibles market as effective alternative to smoked weed
• Cannabis-infused beverage market expected to net revenues between $900 million and $4.4 billion by 2024
• Sproutly building on initial harvest success with planting in remaining Toronto facility flower rooms as it awaits license amendment, new market legalization

Sproutly Canada Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G) is strengthening its cannabis beverage and edibles supply operations as Canada, where it is based, proceeds from legalizing recreational cannabis use for adults last year to legally licensing cannabis edibles and beverages later this year.

Canada’s efforts to establish policy structures for use of the green plant’s long-touted medicinal and relaxing properties, overturning decades of drug war directives, has given it a groundbreaking stature amid the increasingly fertile popular culture granting new acceptance to marijuana and hemp products.

Since listing on the OTC and Canadian exchanges last year, Sproutly Canada has added experienced executives, built its supply networks and increased its output capability in its drive to create the first natural, truly water-soluble cannabis solution that mimics the rapid onset and rapid wear-off effects of inhaled cannabis without the detrimental effects of smoking the product.

A February 13 news release noted additional recent developments in the company’s build-up strategy, including the first two successful harvests of its premium quality, small batch cannabis at its state-of-the-art production facility in Toronto and the migration of its ACMPR license to Canada’s Cannabis Act, which allows it to sell cannabis to other licensed producers (http://ibn.fm/sBISU).

“We are very happy with the results of our first two harvests, which produced highly efficient yields for an initial grow,” Sproutly President Bryan Semkuley stated in a news release. “This is a tremendous milestone for the company, as these harvests are the first step toward our production objectives. We are on track to meet our calendar 2019 production targets and expect multiple successful harvests as we continue to build on this initial success.”

The company is working to produce the same measure of success in the remainder of its 12 flowering rooms at the Toronto Herbal Remedies production facility as the company begins introducing plants in the other rooms this month, planting a new room each week as part of its strategy to maintain a perpetual harvest.

The company has received license amendments allowing it to use the entire THR facility for growing and cultivation operations, and its executives submitted another amendment request in November to allow it to produce cannabis oils through extraction and research operations.

Sproutly’s acquisition of Infusion Biosciences Canada Inc. granted it exclusive access to Infusion’s patent-pending APP Technology, which gently recovers 85 to 90 percent of the total bioactive cannabinoids in plants, including water-soluble cannabinoids and natural oils.

The company is analyzing the benefits of partnering with existing beverage brands, as well as launching its own portfolio of beverages, as it awaits legalization of that market.

“Sproutly has made significant progress towards building a world-class cannabis beverage and infused product company since going public in July of last year,” CEO and Director Keith Dolo stated in the news release.

Analysts at Deloitte peg the potential revenues for the cannabis-infused beverages market at somewhere between $900 million and $4.4 billion by 2024, depending on the percentage of the market that it captures (http://ibn.fm/im9JW). Sproutly’s products have the potential to set their own bar as part of a premium market.

For more information, visit the company’s website at www.Sproutly.ca

• PLUS was the top-selling cannabis-infused brand in California, according to Q4 2018 statistics
• PLUS had three best-selling branded products during that period
• Company widens its position as the market leader, expects momentum to continue in 2019

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) has expanded its leading position in California’s cannabis-infused edibles retail market, with the company now boasting three of the segment’s top five products, according to sales data from BDS Analytics (http://ibn.fm/bL2d6).

PLUS had three best-selling branded products in all categories studied, including vaporizers, flower and edibles and topicals. The company’s Uplift and Restore scored as best-selling stock keeping units (“SKUs”), while its CBD Relief placed number five in best-selling SKUs and was first among CBD-only SKUs.

These statistics reinforce the leadership position of PLUS after it achieved first position in the third quarter of 2018, according to BDS Analytics. During that period, Sour Watermelon Gummies and Blackberry and Lemon Gummies placed in the top two positions across all categories (http://ibn.fm/mTDOI).

In a news release, PLUS CEO Jake Heimark said, “We are proud that we have not only maintained but continued to grow our position as the market leader in Q4. We hope to continue this momentum into 2019, not only in California but in other jurisdictions as well.”

PLUS is a cannabis-infused, branded-products manufacturer selling to regulated medicinal and adult-use recreational markets. PLUS produces product in its 12,000-square-foot cannabis facility in Adelanto, California, and it is focused on building the largest cannabis brand by growing organically and through acquisitions.

For more information, visit the company’s website at www.PlusProducts.com

• Company recently announced significant findings of cardiovascular performance improvements with TurboCBD
• Lexaria plans additional human clinical trials of CBD
• Company is now moving forward with clinical studies on oral forms of nicotine delivery following a large investment agreement

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a food bioscience company that developed and commercialized cost-effective drug delivery platform DehydraTECH. This technology enhances the performance of beneficial compounds in ingestible products. Currently, Lexaria has patents pending worldwide for use of the technology in a range of bioactive molecules, including cannabinoids, nicotine, NSAID pain relievers and more. Leveraging this platform, the taste, smell, speed of action, bioabsorption and bioavailability of oral ingestion is improved without the harmful practices of lighting up or the unhealthy additions of sugars and sweeteners. The company licenses DehydraTECH to other companies around the world to enhance already established, quality product lines.

TurboCBD is Lexaria’s proprietary DehydraTECH-powered, CBD-fortified hemp-oil capsule. The capsules are formulated with full-spectrum hemp oil, ginseng and ginkgo for enhanced focus and memory. They are marketed as a mental and physical boost aimed at helping to remove brain fog, fatigue and stress. TurboCBD is molecularly engineered for quick and high absorption rates into the circulatory system.

In a recent press release (http://ibn.fm/OwOtT), Lexaria announced that the results from a healthy-human clinical trial provided evidence that a single 90mg dose of TurboCBD resulted in lower blood pressure, higher blood flow to the brain, faster delivery onset of CBD into the bloodstream and larger quantities of CBD within the blood as compared to an equal dose of generic CBD. Due to the positive results of this study, the company plans to conduct additional human clinical trials over the course of the next year using DehydraTECH in CBD.

A comprehensive series of clinical studies will also continue on oral forms of nicotine delivery. Lexaria Nicotine LLC, a wholly owned subsidiary, has entered into an investment agreement that will provide an initial $1 million, with additional funding of up to $12 million, toward the research and development of nicotine consumer products enhanced by DehydraTECH.

DehydraTECH is an enabling drug-delivery platform with relevance across multiple industries. The company utilizes subsidiaries that reach across industry lines, making it accessible to the medical and recreational cannabis industries and pharmaceutical sectors. The company has formed a partnership with one of the world’s largest tobacco companies (http://ibn.fm/v91xQ). Currently, Lexaria owns 10 patents with over 50 patents pending worldwide for this revolutionary technology. Lexaria is ahead of the game, doing business on its terms and attracting the attention of Fortune 500-type corporations.

For more information, visit the company’s website at www.LexariaBioscience.com

• CIIX recently established a new website to present its domestic CBD line and offer consumers one-stop shopping convenience
• CIIX’s CBD Biotechnology Co. Ltd has a separate line designed for the Chinese market
• CIIX CEO says that additional opt brand industrial hemp-infused CBD products will be developed and introduced

ChineseInvestors.com Inc. (OTCQB: CIIX) has moved to rebrand subsidiary ChineseHempOil.com Inc.’s consumer products line under the new ‘opt’ brand. The brand unifies its domestic industrial hemp-infused consumer products and features two lines: opt Hemp and opt2mist (http://ibn.fm/7IU4K).

The opt Hemp currently line includes gummies, oils, soft gels and cosmetics. It also consists of other hemp-derived CBD products in development.

The company’s opt2mist is a spray-vitamin line of products in development that will also include full-spectrum, hemp-derived CBD-infused formulas.

In a news release, CIIX CEO Warren Wang stated, “The unification of our domestic consumer products under the opt brand is a step in the right direction to building optimal brand recognition as we continue to roll out our new industrial, hemp-infused CBD products and other health and wellness products, such as the opt2mist sprays, throughout 2019 and beyond.”

CIIX has also set up a new website, www.365CWC.com, to present the products with brand appeal. “The consolidation of our domestic consumer sites into a single channel will provide a one-stop shop for busy consumers, which, in turn, we believe will ultimately drive sales,” Wang added.

CIIX’s wholly owned foreign entity, CBD Biotechnology Co. Ltd., has separate products created for the Chinese market. These include a skin care line featuring the Live Oxygen luxury products and CBD Magic Hemp series, plus its self-branded, hemp-infused rice wine, CBD Biotech Hemp Wine. Live Oxygen and Magic Hemp are featured on e-commerce site Alibaba, which has 500 million registered users.

For more information, visit the company’s website at www.ChineseInvestors.com

• ETST recently announced a distribution agreement to market Hygee in Vietnam
• The company also provided an update on the its CBD product line
• ETST signed agreements with CannaBiz Deals and Desert Sun Distribution to distribute its CBD line throughout the United States
• Company’s white labeling initiative is now in progress

Florida-based biotech company Earth Science Tech Inc. (OTCQB: ETST) is focused on cannabis, industrial hemp and cannabinoid research and development; nutraceuticals; pharmaceuticals; and medical devices. The company operates through four wholly owned subsidiaries:

• Earth Science Pharmaceutical Inc. develops low-cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases).
• Cannabis Therapeutics Inc. is poised to become a world leader in cannabinoid research and development for a broad line of cannabinoid-based pharmaceuticals and nutraceuticals, as well as other products and solutions.
• KannaBidioid Inc. is focused on the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles featuring its unique Kanna and CBD formula.
• Canna Inno Laboratories Inc. provides ETST a foothold in Québec and access to government grants, the first of which has just been approved.

The company is nearing completion of its first commercial batch of Hygee, a new original medical device to fight STIs. This self-sampling kit provides women with a discreet and effective way to anonymously test for STIs such as chlamydia. Since chlamydia infections can be passed from mother to infant during childbirth, this test has the potential to revolutionize women’s health. Approximately eight million women give birth every year in the areas that Hygee will first be offered, including the United States, Canada, Brazil, Mexico, Morocco, Djibouti and Vietnam (http://ibn.fm/FjacD).

Queen Concept Inc. will be the exclusive distributor of Hygee in Vietnam for the next five years, according to a new distribution agreement with ETST (http://ibn.fm/HWfW9). In Vietnam, approximately 7.5 million women fall within the demographic of those recommended to test for chlamydia every year. This demographic includes pregnant women and sexually active women who are between the ages of 15 and 25.

“We are ready to export Hygee in Asia and the Middle East — starting with Vietnam — which will act as a proving ground for the coming introduction of Hygee in the other countries we will target,” ETST Chairman Nickolas Tabraue stated in a news release. “Our testing protocols are ready to conduct high throughput screening for genital chlamydia anywhere around the world.”

The company also announced the upcoming launch of three CBD products (http://ibn.fm/PHTF1). The first of the products will be PropoDiol throat spray. ETST worked with Laboratoir Binatus Pharmacognosique Inc. to improve the existing Propovit throat spray. The main ingredient of the spray is propolis, a compound derived from the Brazilian green bee. The new formulation combines the strong antioxidants and potent antibacterial, antiviral, antifungal and anti-inflammatory properties of propolis with ETST’s full-spectrum cannabinoids. The result, PropoDiol, is a CBD-enriched, strawberry-flavored throat spray.

In early February 2019, a press release (http://ibn.fm/ovj3l) announced that the company has signed agreements for CannaBiz Deals and Desert Sun Distribution to distribute its CBD line through pharmacies, chiropractors, dispensaries, athletic clubs and clinics in the United States. David Barbash, ETST’s chief sales officer, has implemented broad strategies to expand the company’s sales team to explore product placement. Barbash has stated that these new distribution agreements “are only a fraction of the opportunities we see for our CBD products.”

In addition, ETST is collaborating with its manufacturing partner to launch a white labeling initiative. The white label will allow other marketers to rebrand ETST’s High Grade Full Spectrum CBD line. For the last three quarters, the company’s sales have increased more than 100 percent every month, and ETST notes that inquiries regarding white labeling have been on the rise.

Tabraue added, “We have a lot of opportunity on deck for 2019, and we look forward to sharing the results of our strategies.”

For more information, visit the company’s website at www.EarthScienceTech.com

• SING’s strategic entry into the legal cannabis industry was boosted by U.S. legalization of hemp
• Subsidiary SingleSeed.com is targeting the multibillion-dollar global pet care market with its best-selling Phyto-Bites CBD for all sizes of dogs
• SinglePoint begins busy 2019 trade show circuit at CHAMPS premier counterculture B2B expo in Las Vegas, February 27-March 1

SinglePoint Inc. (OTCQB: SING), a technology company providing mobile payments and ancillary cannabis services, is positioned to take advantage of the newly legalized U.S. hemp industry with its growing portfolio of hemp and cannabidiol (“CBD”) products, available through subsidiary SingleSeed.com. In an investor update, SinglePoint President Wil Ralston shared the company’s immediate plans to expand its offerings in the CBD space, which has seen a significant boost since the 2018 Farm Bill passed Congress and was signed by President Donald Trump (http://ibn.fm/NXAJE).

“We’ve been getting so many calls about CBD and isolate products. SingleSeed has really started to ramp up the amount of sales we’ve seen come through the ecommerce channel,” Ralston told investors in a video update. “It’s been an exciting time. We’re seeing more sales and increased inquiries about CBD products, especially isolate. We’re doing a wonderful job of connecting different entities together for the purchase and sale of isolate, which is great. It’s opening doors for a lot of relationships.”

SinglePoint is exploring opportunities to produce industrial hemp through joint venture opportunities with agricultural growers. The company has also placed an investment in a program that would grow hemp strains of CBD in a photobioreactor as an initiative to reduce the cost and time involved in making a potentially pharmaceutical-grade product (http://ibn.fm/USW2X).

SinglePoint’s best-selling CBD product to date on its SingleSeed ecommerce platform is Phyto-Bites, Ralston said. Phyto-Bites are a soft chew, branded product formulated to reduce stress, pain, separation anxiety and inflammation – particularly for dogs. The company is working with manufacturer CBD Unlimited (formerly Endexx) to distribute the product online and in stores across the nation (http://ibn.fm/QDbpv). A recent Grand View Research report estimates that the global pet care market could reach $202.6 billion by 2025 (http://ibn.fm/kqcfT).

“We’re very excited about that and look forward to adding additional products to our bag for both retail stores and our online channels,” Ralston said of the increasing demand for Phyto-Bites, which necessitated hiring additional people to help fulfill the amount of sales coming through the online portal.

SingleSeed provides various services to cannabis enterprises, becoming a hub for dispensaries seeking merchant payment processing solutions and other business tools. Through SingleSeed.com, SinglePoint offers payment processing and text message marketing solutions that are specifically designed for cannabis businesses (http://ibn.fm/grYm6).

Ralston said that SinglePoint is receiving a lot of inquiries about distribution and is making inroads into the retail sector. The company is putting the finishing touches on a wholesale agreement for a distributor that is working from Fresno to Sacramento, California, with 120 distribution points. SinglePoint management plan to attend multiple tradeshows throughout 2019, with the first of many appearances scheduled in Las Vegas, February 27 to March 1, at CHAMPS, the premier counterculture B2B expo since 1999 (http://ibn.fm/1ewZF).

“We’ll have a booth there and we’re looking forward to making a lot of relationships,” Ralston noted. “Hopefully we’ll see some of you all there and have some great conversations about what SinglePoint has been doing and some of our subsidiaries, such as SingleSeed, and their growth potential.”

For more information, visit the company’s website at www.SinglePoint.com